Market news
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier. For the first half of 2026, the company also reduced its net loss to US$46.33 million, or US$0.74 per share, signaling improving cost control and operating efficiency versus the prior-year period. We will now examine how Janux Therapeutics' reduced net loss and improving...
Detailed price information for Janux Therapeutics Inc (JANX-Q) from The Globe and Mail including charting and trades.
SAN DIEGO, August 06, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update.
In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...
This is the newest page. Registered accounts read further back.